Raymond James analyst John Hsu notes that CareDx (CDNA) announced the filing of a patent infringement lawsuit against Natera (NTRA), which was “not unexpected.” The analyst sees the lawsuit as consistent with management seeking to protect the company’s intellectual property, and notes that the court process could take up to three years. While this lawsuit is a “logical course of action,” Hsu believes CareDx remains focused on building its moat in kidney transplant, with sales force investments and a focus on integration with hospital electronic medical records. Overall, the analyst still views 2019’s main focus on other activities to strengthen a “significant head start on the back of a best-in-class product launch in 2018.” He reiterates a Strong Buy rating on CareDx shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.